Characterization of Clinical Phenotypes of Laryngeal Dystonia and Voice Tremor

Description

The researchers will systematically evaluate current and novel clinical voice assessment tools and measures to elucidate distinct clinical phenotypes of those with laryngeal dystonia and voice tremor.

Conditions

Laryngeal Dystonia, Spasmodic Dysphonia, Tremor

Study Overview

Study Details

Study overview

The researchers will systematically evaluate current and novel clinical voice assessment tools and measures to elucidate distinct clinical phenotypes of those with laryngeal dystonia and voice tremor.

Characterization of Clinical Phenotypes of Laryngeal Dystonia and Voice Tremor

Characterization of Clinical Phenotypes of Laryngeal Dystonia and Voice Tremor

Condition
Laryngeal Dystonia
Intervention / Treatment

-

Contacts and Locations

Boston

Massachusetts Eye and Ear and University of Utah, Boston, Massachusetts, United States, 02114

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Males and females of diverse racial and ethnic backgrounds;
  • 2. Age 18-80 years;
  • 3. Native English speakers;
  • 4. Right-handed;
  • 5. Normal cognitive status;
  • 6. Patients will have laryngeal dystonia or voice tremor;
  • 7. Healthy controls will be healthy individuals without neurological, psychiatric or otolaryngological problems.
  • 1. Subjects who are incapable of giving informed consent;
  • 2. Pregnant or breastfeeding women until a time when they are no longer pregnant or breastfeeding. All women of childbearing potential will have a urine pregnancy test performed before MRI, which must be negative for participation in the imaging studies;
  • 3. Subjects with a past or present medical history of (a) neurological problems, such as stroke, movement disorders (other than specified LD and VT in the patient groups), brain tumors, traumatic brain injury with loss of consciousness, ataxias, myopathies, myasthenia gravis, demyelinating diseases; (b) psychiatric problems, such as schizophrenia, bipolar depression, obsessive-compulsive disorder, alcoholism, drug dependence; (c) laryngeal problems, such as vocal fold paralysis, paresis, vocal fold nodules and polyps, carcinoma, chronic laryngitis;
  • 4. Patients with any other form of dystonia;
  • 5. Patients who have dystonia symptoms at rest or have a presence of mirror dystonia;
  • 6. Patients who are not symptomatic due to treatment with botulinum toxin injections into the affected muscles. The duration of positive effects of botulinum toxin varies from patient to patient but lasts, on average, for 3-4 months. All patients will be evaluated to ensure that they are fully symptomatic and are at least 3 months post-injection before participation;
  • 7. To avoid the confounding effect of centrally acting drugs, all study participants will be questioned about any prescribed or over-the-counter medications as part of their initial screening. Those patients who receive medication(s) affecting the central nervous system will be excluded;
  • 8. Patients will be asked whether they have undergone any head or neck surgery, which resulted in changes in regional anatomy or innervation. Because brain or laryngeal surgery may potentially lead to brain structure and function re-organization, all patients with such a history will be excluded;
  • 9. Subjects who have certain tattoos and ferromagnetic objects in their bodies (e.g., implanted stimulators, surgical clips, prosthesis, artificial heart valve) that cannot be removed for MRI studies.

Ages Eligible for Study

18 Years to 80 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Massachusetts Eye and Ear Infirmary,

Kristina Simonyan, MD, PhD, STUDY_DIRECTOR, Massachusetts Eye and Ear

Study Record Dates

2026-08-31